Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978611 | 1.00 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTALOX5POLB | |
| SCHEMBL6752 | 0.89 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTALOX5POLB | |
| SCHEMBL29901720 | 0.89 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTALOX5POLB | |
| SCHEMBL7349545 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTPOLBGAA | |
| SCHEMBL23611043 | 0.83 | ALOX5 (0.48) | ALDH1A1LMNAMAPTALOX5CRBN | |
| SCHEMBL25720031 | 0.82 | GAA (0.52) | ALDH1A1MAPTPOLBGAAPKM | |
| SCHEMBL941445 | 0.82 | GAA (0.56) | ALDH1A1LMNAMAPTALOX5GAA | |
| SCHEMBL13932092 | 0.81 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTPOLBGAA | |
| SCHEMBL4265304 | 0.81 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTPOLBGAA | |
| SCHEMBL3283784 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-4384268-B1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT LTD (IN) | 2026-03-18 | — | — | EP | disclosed |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| CN-115151304-B | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2024-10-31 | — | — | US | disclosed |
| EP-4384268-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | disclosed |
| CN-118019738-A | Small molecule urea derivatives as STING antagonists | 库拉德夫制药私人有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-1060769-C | 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof | KENEBO LTD (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-0719766-B1 | 1,4-Benzoxazine derivative, pharmaceutical composition containing the same and use thereof | KANEBO LTD (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0543997-B1 | DERIVATIVES OF METHOTREXATE WITH ANTIRHEUMATIC ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-5597820-A | CARDIOVASCULAR DISORDERS | KANEBO, LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| CN-1032858-C | Methylamino pterin derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1996-09-25 | — | — | CN | disclosed |
| CN-1130183-A | 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof | KANEBO LTD (JP) | 1996-09-04 | — | — | CN | disclosed |
| EP-0719766-A1 | 1,4-Benzoxazine derivative, pharmaceutical composition containing the same and use thereof | KANEBO LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5354753-A | Methotrexate derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0543997-A1 | NOVEL METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-06-02 | — | — | EP | disclosed |
| CN-1059725-A | Novel methotrexate derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1992-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | STING1, CGAS, SSB | ALDH1A1 3165/4885LMNA 1842/4885MAPT 2509/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | ALDH1A1 4559/4885LMNA 3179/4885MAPT 2156/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | ALDH1A1 3672/4885LMNA 2127/4885MAPT 3716/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | ALDH1A1 1185/4885LMNA 2783/4885MAPT 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.